Mb Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 24-06-2024
- Paid Up Capital ₹ 0.10 M
as on 24-06-2024
- Company Age 11 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -89.35%
(FY 2020)
- Profit -103.24%
(FY 2020)
- Ebitda -88.28%
(FY 2020)
- Net Worth -125.50%
(FY 2020)
- Total Assets -99.02%
(FY 2020)
About Mb Lifesciences
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Nagendra Lenka and Sachin Sharma serve as directors at the Company.
- CIN/LLPIN
U33110DL2013PTC247327
- Company No.
247327
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Jan 2013
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Central Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Mb Lifesciences Private Limited offer?
Mb Lifesciences Private Limited offers a wide range of products and services, including Mineral Supplement, Calcium Tablet, Pain Balm & Ointments, Ayurvedic Pain Balm, Diabetic Herbal Medicine, Diabetic Herbal Tablets & Capsules, Herbal Skin Care Cosmetics, Herbal Cream, Herbal Oil, Herbal Medicinal Oil.
Who are the key members and board of directors at Mb Lifesciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nagendra Lenka  | Director | 13-Dec-2021 | Current |
| Sachin Sharma | Director | 16-Nov-2021 | Current |
Financial Performance of Mb Lifesciences.
Mb Lifesciences Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 89.35% decrease. The company also saw a substantial fall in profitability, with a 103.24% decrease in profit. The company's net worth observed a substantial decline by a decrease of 125.5%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mb Lifesciences?
In 2018, Mb Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Mb Lifesciences?
Unlock and access historical data on people associated with Mb Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mb Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mb Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
